Project Grant R01CA305978
Award Date 6/2/26
Completion Date 5/31/31
Dollars Obligated $720K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Health Research, Inc. (operating as Health Research At Roswell Park) a Project Grant totaling $639,379 under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2031. This award supports research addressing PAR-24-306 (Research Projects to Enhance Applicability of Mammalian Models for Translational Research), specifically focused on developing and validating neuroendocrine...
- Federal Grant Award Summary Health Research, Inc. (operating as Health Research at Roswell Park) received a $173,500 Project Grant awarded August 7, 2025, by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to conduct a correlative clinical study investigating the effects of CXCR1/2 inhibition on the immune microenvironment of multiple myeloma patients. The research leverages preliminary findings demonstrating significant accumulation of CXCR2-positive...
- Federal Project Grant Award Summary The National Cancer Institute awarded $433,256 under the Cancer Treatment Research program (CFDA 93.395) to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., for a two-year project (June 1, 2026 – May 31, 2028) focused on fragment-based drug discovery targeting epithelial-to-mesenchymal transition (EMT)-mediated resistance in EGFR (epidermal growth factor receptor)-mutant lung cancer. The research employs fragment-based chemical...
- Federal Project Grant Award Summary New York University School of Medicine received a $315,246 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective August 1, 2025, through July 31, 2030. This five-year research initiative, titled "Breaking Cytokine Loops in Lung Adenocarcinoma," will deliver fundamental cancer research and scientific investigation focused on understanding immune resistance mechanisms in lung cancer...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $182,755.00 to Cold Spring Harbor Laboratory through the Cancer Biology Research program (CFDA 93.396) to support research on genetic technology development for elucidating lineage plasticity mechanisms in cancer. The project, which commenced on August 21, 2025, and is scheduled for completion on July 31, 2030, will deliver advanced genetic screening technologies and methodologies designed to probe lineage identity...
- Federal Grant Award Summary Health Research, Inc. (operating as Health Research At Roswell Park) received a $713,312 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 1, 2026, through May 31, 2031. The award funds research to elucidate the impacts of body composition and physical activity on anti-tumor immunity and cancer control in advanced-stage high-grade serous ovarian carcinoma (HGSOC). The research...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $1.056 million to the Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) to support research on overcoming resistance to targeted therapies in breast cancer. Initiated August 20, 2025, and extending through July 31, 2032, this project delivers fundamental and applied research aimed at understanding and addressing the development of drug resistance in...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $682,673 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for research on "Adaptation and Evolution of Resistance to Pan-RAS Inhibition in Pancreatic Ductal Adenocarcinoma." The five-year project, spanning May 1, 2026 through April 30, 2031, supports fundamental and applied research investigating mechanisms of tumor resistance to pan-RAS...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $472,730 project grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025, through July 31, 2030. This five-year project investigates the role of the tumor suppressor KEAP1 (Kelch-like ECH-associated protein 1) in antitumor immunity, with specific focus on understanding how loss-of-function KEAP1 mutations contribute to immune...